TrialCancer medicine2026

Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.

Naoto Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.